IL142906A0 - Methods and compositions for treating or preventing peripheral neuropathies - Google Patents

Methods and compositions for treating or preventing peripheral neuropathies

Info

Publication number
IL142906A0
IL142906A0 IL14290699A IL14290699A IL142906A0 IL 142906 A0 IL142906 A0 IL 142906A0 IL 14290699 A IL14290699 A IL 14290699A IL 14290699 A IL14290699 A IL 14290699A IL 142906 A0 IL142906 A0 IL 142906A0
Authority
IL
Israel
Prior art keywords
compositions
treating
methods
peripheral neuropathies
preventing peripheral
Prior art date
Application number
IL14290699A
Other languages
English (en)
Original Assignee
Biogen Inc
Ontogeny Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc, Ontogeny Inc filed Critical Biogen Inc
Publication of IL142906A0 publication Critical patent/IL142906A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Addiction (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
IL14290699A 1998-11-06 1999-11-08 Methods and compositions for treating or preventing peripheral neuropathies IL142906A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/187,387 US20030083242A1 (en) 1998-11-06 1998-11-06 Methods and compositions for treating or preventing peripheral neuropathies
PCT/US1999/026334 WO2000027422A2 (fr) 1998-11-06 1999-11-08 Methodes et compositions permettant de traiter ou de prevenir des neuropathies peripheriques

Publications (1)

Publication Number Publication Date
IL142906A0 true IL142906A0 (en) 2002-04-21

Family

ID=22688771

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14290699A IL142906A0 (en) 1998-11-06 1999-11-08 Methods and compositions for treating or preventing peripheral neuropathies

Country Status (7)

Country Link
US (1) US20030083242A1 (fr)
EP (1) EP1126865A2 (fr)
JP (1) JP2002529423A (fr)
AU (1) AU776265B2 (fr)
CA (1) CA2349498A1 (fr)
IL (1) IL142906A0 (fr)
WO (1) WO2000027422A2 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1223937A2 (fr) * 1999-10-07 2002-07-24 Novaneuron Inc. Gene necessaire a la fonction striatale, ses applications et composes permettant de moduler ce gene
US6903073B2 (en) * 1999-12-10 2005-06-07 The General Hospital Corporation Methods to stimulate insulin production by pancreatic beta-cells
EP1645275A1 (fr) * 2000-03-30 2006-04-12 Curis, Inc. Petites molécules organiques comme régulateurs de la prolifération céllulaire
US8852937B2 (en) 2000-03-30 2014-10-07 Curis, Inc. Small organic molecule regulators of cell proliferation
US7115653B2 (en) 2000-03-30 2006-10-03 Curis, Inc. Small organic molecule regulators of cell proliferation
DE60113823T3 (de) * 2000-03-30 2010-07-01 Curis, Inc., Cambridge Kleine organische moleküle als regulatoren der zellproliferation
WO2001082946A2 (fr) * 2000-04-28 2001-11-08 Curis, Inc. Compositions neuroprotectrices
AU2001275495B2 (en) * 2000-06-16 2006-08-17 Curis, Inc. Angiogenesis-modulating compositions and uses
ATE508188T1 (de) 2002-02-01 2011-05-15 Life Technologies Corp Oligonukleotid-zusammensetzungen mit verbesserter wirksamkeit
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
US20030157185A1 (en) * 2002-02-08 2003-08-21 Lou Paradise Topical treatment of neuropathy
US7871647B1 (en) * 2002-02-08 2011-01-18 TPR International, Inc Topical treatment of neuropathy
KR100533794B1 (ko) * 2003-10-02 2005-12-07 주식회사 프로젠 인간 난포자극 호르몬을 대량으로 생산하는 방법
US20050208671A1 (en) * 2003-12-26 2005-09-22 Nof Corporation Method of analyzing the ratio of activation of terminals of polyoxyalkylene derivatives
WO2006002422A2 (fr) 2004-06-24 2006-01-05 Novartis Vaccines And Diagnostics Inc. Composes utilises pour l'immunopotentialisation
WO2006079068A2 (fr) * 2005-01-20 2006-07-27 University Of Rochester Compositions et methodes permettant d'etudier et de traiter des maladies et des troubles inflammatoires
US20070059311A1 (en) * 2005-09-12 2007-03-15 Jingwu Xie Regulation of the hedgehog signaling pathway and uses thereof
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
TW200808739A (en) 2006-04-06 2008-02-16 Novartis Vaccines & Diagnostic Quinazolines for PDK1 inhibition
US20070275008A1 (en) * 2006-05-26 2007-11-29 Olalde Rangel Jose A Synergistic Diabetic Phyto-Nutraceutical Composition
US8273747B2 (en) 2006-11-02 2012-09-25 Curis, Inc. Small organic molecule regulators of cell proliferation
US7553501B2 (en) * 2006-11-16 2009-06-30 Jose Angel Olalde Rangel Immune phyto-neutraceutical composition
PE20091523A1 (es) 2007-12-20 2009-10-29 Novartis Ag Derivados de tiazol como inhibidores de la enzima fosfatidilinositol 3-cinasa (pi3k)
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
AR082418A1 (es) 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
UY33883A (es) 2011-01-31 2012-08-31 Novartis Ag Novedosos derivados heterocíclicos
US8557513B2 (en) * 2011-06-27 2013-10-15 Biocrine Ab Methods for treating and/or limiting development of diabetes
AP2014007601A0 (en) 2011-10-28 2014-04-30 Novartis Ag Novel purine derivatives and their use in the treatment of disease
NZ700924A (en) 2012-05-16 2016-02-26 Novartis Ag Dosage regimen for a pi-3 kinase inhibitor
DK3076969T3 (da) 2013-12-06 2021-11-22 Novartis Ag Doseringsregime for en alfa-isoform-selektiv phosphatidylinositol-3-kinase-hæmmer
RU2018119085A (ru) 2015-11-02 2019-12-04 Новартис Аг Схема введения ингибитора фосфатидилинозитол-3-киназы
WO2018060833A1 (fr) 2016-09-27 2018-04-05 Novartis Ag Schéma posologique pour l'alpelisib, un inhibiteur de la phosphatidylinositol 3-kinase spécifique de l'isoforme alpha
CN106814171B (zh) * 2017-01-18 2019-02-19 江南大学 一种利用数学模型确定食用油中植物甾醇添加量的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5789543A (en) * 1993-12-30 1998-08-04 President And Fellows Of Harvard College Vertebrate embryonic pattern-inducing proteins and uses related thereto
NZ278765A (en) * 1993-12-30 1998-05-27 Harvard College Vertebrate proteins involved in spatial arrangements of differentiated tissues called hedgehog proteins, their production and use
US7144997B2 (en) * 1997-07-24 2006-12-05 Curis, Inc. Vertebrate embryonic patterning-inducing proteins, compositions and uses related therto
CA2302780A1 (fr) * 1997-08-29 1999-03-04 Ontogeny, Inc. Regulation de tissus musculaires par des polypeptides "hedgehog", et formulations et utilisations associees
WO1999029854A1 (fr) * 1997-12-08 1999-06-17 Ontogeny, Inc. Genes et proteines ptc humains, et leurs utilisations

Also Published As

Publication number Publication date
AU1611600A (en) 2000-05-29
WO2000027422A2 (fr) 2000-05-18
US20030083242A1 (en) 2003-05-01
EP1126865A2 (fr) 2001-08-29
CA2349498A1 (fr) 2000-05-18
JP2002529423A (ja) 2002-09-10
AU776265B2 (en) 2004-09-02
WO2000027422A3 (fr) 2000-11-09

Similar Documents

Publication Publication Date Title
IL142906A0 (en) Methods and compositions for treating or preventing peripheral neuropathies
GR20010300060T1 (en) Methods and compositions for treating and preventing mucositis
HUP0103920A3 (en) Methods and compositions for the prevention and treatment of anemia
AUPQ127399A0 (en) Compositions and methods for treating or preventing osteoporosis
AU6053900A (en) Compositions for treating or preventing neurodegeneration and cognitive decline
HUP0201436A3 (en) Methods and compositions for treating solid tumors
PL352014A1 (en) Dietetic of pharmacological composition for preventing or treating hyperoxaluria
HK1031174A1 (en) Compositions and methods for treating diabetes
IL127664A (en) Compositions for the treatment and prevention of cachexia
HU9802721D0 (en) Method and composition for the treatment and prevention of hyperuricemia
ZA988016B (en) Compounds methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
HUP0104688A3 (en) Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
BG105437A (en) REFLECTIVELY MODIFIED COMPOSITIONS AND METHODS FOR OBTAINING THEM
EP1109548A4 (fr) Utilisation de procedes et de compositions a base de tocotrienols pour traiter et prevenir les maladies osseuses
ZA981600B (en) Methods and compositions for treating stickies
IL124650A0 (en) Methods and therapeutic compositions for treating cancer
IL141426A0 (en) Compositions and methods for the treatment of tumor
HK1042847A1 (zh) 骨代謝異常症治療劑
IL143212A0 (en) Compositions and methods for the treatment of tumor
GB9805744D0 (en) Biocidal compositions and treatments
HUP0102995A3 (en) Agents and method for the protective treatment of wood
PL331283A1 (en) Preparation for treating and/or preventing stupefaction
AU5243999A (en) Methods and compositions for treating and preventing substance abuse using moclobemide
GB9810540D0 (en) Methods and compositions for preventing and treating bone loss
HUP0100613A3 (en) Methods and compositions for stabilizing acetylcholine compositions

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees